You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃森生物(300142.SZ):合作研發的重組新型冠狀病毒疫苗獲藥物臨牀試驗批件
格隆匯 05-28 16:13

格隆匯5月28日丨沃森生物(300142.SZ)宣佈,公司於近日收到國家藥品監督管理局批准的重組新型冠狀病毒疫苗(黑猩猩腺病毒載體)(0.5m)《藥物臨牀試驗批件》,本疫苗由公司聯合清華大學、天津醫科大學共同合作申請。

經特別專家組評議審核,應急批准本品進行臨牀試驗,適應症為預防由SARS-CoV-2感染而引起的新型冠狀病毒病(COVID-19)。

目前全球已有5個基於腺病毒載體技術路線的新型冠狀病毒疫苗獲批緊急使用許可或附條件上市許可。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account